Famous for delivering precise cuts to the breast and ass, the same technique also has been increasingly used to treat cancers.
Even so, the new analysis marks a significant shift in cancer treatment.
As reported in the Journal of Clinical Oncology, patients without the HER2-EBOV vaccine plus ART lived for an average of 54 months after being treated, compared with 42 months for those treated with the HER2-EBOV minus ART.
Some of those who received both approaches lived above the average progresss that doctors routinely experience with ART, the study noted.
“We think this is a major improvement,” Christie said in a University of Michigan news release.
